Paul Hudson, Sanofi CEO (Jeremy Paoloni/Abaca/Sipa USA(Sipa via AP Images))
Despite oncology cutbacks, Sanofi isn’t out of the game yet with early assets
Sanofi is keeping an early pipeline of oncology projects even as it axed clinical-stage programs and reallocated resources to immunology, CEO Paul Hudson told reporters …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
